Braveheart Bio, Inc. (BRVE) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.72B USD. 52-week range 17.86 to 32.00 USD. Data as of 2026-10-09.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.